Investing IdeasBrowse All StocksMarkets
Have your own idea? Try our Stock Screener
Header cover image

U.S. Biotech Industry Analysis

UpdatedAug 03, 2026
DataAggregated Company Financials
Companies549
  • 7D-0.7%
  • 3M6.3%
  • 1Y29.6%
  • YTD8.7%

The Biotech is pretty flat in the last 7 days, but Regeneron Pharmaceuticals has stood out, gaining 16%. The past year has been better, since the industry has gained 30% in that time. As for the next few years, earnings are expected to grow by 24% per annum.

Industry Valuation and Performance

Has the U.S. Biotech Industry valuation changed over the past few years?

DateMarket CapRevenueEarningsPEAbsolute PEPS
Tue, 04 Aug 2026US$1.4tUS$171.5b-US$12,026,135,280.1917x-114.1x8x
Thu, 02 Jul 2026US$1.4tUS$169.9b-US$12,048,878,572.8016.8x-117x8.3x
Sat, 30 May 2026US$1.3tUS$170.1b-US$12,180,295,874.9216.2x-107.3x7.7x
Mon, 27 Apr 2026US$1.3tUS$166.0b-US$11,982,883,986.9917.8x-108.4x7.8x
Wed, 25 Mar 2026US$1.3tUS$169.3b-US$15,116,425,731.1116.9x-83.4x7.4x
Fri, 20 Feb 2026US$1.3tUS$167.6b-US$13,402,775,963.6722x-100.1x8x
Sun, 18 Jan 2026US$1.2tUS$163.5b-US$15,150,311,707.6019.7x-80.8x7.5x
Tue, 16 Dec 2025US$1.2tUS$163.7b-US$15,629,182,813.9318.8x-78x7.4x
Thu, 13 Nov 2025US$1.2tUS$163.7b-US$16,361,101,083.0018.3x-72.3x7.2x
Sat, 11 Oct 2025US$1.2tUS$163.4b-US$18,215,346,855.4416.6x-63.1x7x
Mon, 08 Sep 2025US$1.1tUS$163.6b-US$18,346,659,491.1215.7x-58.9x6.6x
Wed, 06 Aug 2025US$1.0tUS$159.3b-US$15,865,734,075.2016.7x-65x6.5x
Fri, 04 Jul 2025US$960.1bUS$155.8b-US$23,422,935,456.9917.3x-41x6.2x
Sun, 01 Jun 2025US$908.1bUS$155.8b-US$23,980,173,787.0415.6x-37.9x5.8x
Tue, 29 Apr 2025US$784.0bUS$119.2b-US$31,078,506,586.1420.3x-25.2x6.6x
Thu, 27 Mar 2025US$827.3bUS$118.5b-US$36,884,032,976.2619.9x-22.4x7x
Sat, 22 Feb 2025US$863.3bUS$117.3b-US$37,606,528,073.3717x-23x7.4x
Mon, 20 Jan 2025US$947.4bUS$149.4b-US$26,286,185,460.0517.3x-36x6.3x
Wed, 18 Dec 2024US$996.7bUS$149.9b-US$26,485,748,422.0216.6x-37.6x6.6x
Fri, 15 Nov 2024US$1.1tUS$150.0b-US$27,266,729,255.6217.3x-39x7.1x
Sun, 13 Oct 2024US$902.0bUS$113.1b-US$36,040,263,614.5420.6x-25x8x
Tue, 10 Sep 2024US$894.1bUS$113.1b-US$35,658,177,880.3622.2x-25.1x7.9x
Thu, 08 Aug 2024US$1.2tUS$166.2b-US$32,645,503,888.5223.4x-35.8x7x
Sat, 06 Jul 2024US$1.1tUS$164.5b-US$28,073,491,589.9727.9x-39.9x6.8x
Mon, 03 Jun 2024US$1.1tUS$164.6b-US$26,677,143,877.6527.4x-42.1x6.8x
Wed, 01 May 2024US$1.1tUS$164.6b-US$27,373,262,846.2322.9x-39.5x6.6x
Fri, 29 Mar 2024US$1.2tUS$164.4b-US$23,753,804,933.9221.4x-49.6x7.2x
Sun, 25 Feb 2024US$1.2tUS$166.6b-US$21,694,949,476.2110.8x-54.3x7.1x
Tue, 23 Jan 2024US$1.4tUS$204.8b-US$22,505,965,323.0018.5x-63.5x7x
Thu, 21 Dec 2023US$1.4tUS$204.8b-US$22,158,313,482.0018.8x-61.2x6.6x
Sat, 18 Nov 2023US$1.2tUS$204.7b-US$22,079,363,558.0018.1x-54.7x5.9x
Mon, 16 Oct 2023US$1.3tUS$207.3b-US$13,079,327,258.0016.6x-96.8x6.1x
Wed, 13 Sep 2023US$1.3tUS$207.5b-US$12,640,460,182.0017.5x-101.7x6.2x
Fri, 11 Aug 2023US$1.3tUS$207.7b-US$12,610,114,686.0017.6x-101.5x6.2x
Price to Earnings Ratio

-101.5x


Total Market Cap: US$1.3tTotal Earnings: -US$12,610,114,686.00Total Revenue: US$207.7bTotal Market Cap vs Earnings and Revenue0%0%0%
U.S. Biotech Industry Price to Earnings3Y Average -60.4x202420252026
Current Industry PE
  • Investors are optimistic on the American Biotechs industry, and appear confident in long term growth rates.
  • The 3-year average PS ratio of 7.0x is lower than the industry's current PS ratio of 8.0x.
Past Earnings Growth
  • Losses for companies in the Biotechs industry have remained mostly flat over the last three years.
  • Meanwhile revenues for these companies have declined 6.2% per year.
  • This means that the cost of doing business could be reducing since sales have declined but losses haven't fallen much further.

Industry Trends

Which industries have driven the changes within the U.S. Healthcare industry?

US Market0.85%
Healthcare-0.58%
Biotech-0.70%
Biotech-0.70%
Industry PEThere are no additional sub-industries under this industry.
Forecasted GrowthThere are no additional sub-industries under this industry.

Top Stock Gainers and Losers

Which companies have driven the market over the last 7 days?

CompanyLast Price7D1YValuation
REGN Regeneron PharmaceuticalsUS$759.249.2%
+US$5.1b		33.2%PE17.5x
NTRA NateraUS$270.367.2%
+US$2.6b		92.9%PS15.5x
TWST Twist BioscienceUS$101.0614.1%
+US$779.0m		267.2%PS14.6x
CDNA CareDxUS$47.8533.8%
+US$628.7m		272.4%PE22.3x
REPL Replimune GroupUS$11.91122.6%
+US$550.8m		88.4%PB6x

Latest News

ABBV
US$245.10
AbbVie
7D
-6.9%
1Y
23.4%
REGN
US$759.24
Regeneron Pharmaceuticals
7D
9.2%
1Y
33.2%
TWST
US$101.06
Twist Bioscience
7D
14.1%
1Y
267.2%
AMGN
US$378.87
Amgen
7D
-3.6%
1Y
26.3%
REPL
US$11.91
Replimune Group
7D
122.6%
1Y
88.4%
NBIX
US$166.23
Neurocrine Biosciences
7D
-9.1%
1Y
29.5%
CDNA
US$47.85
CareDx
7D
33.8%
1Y
272.4%
PGEN
US$6.61
Precigen
7D
19.5%
1Y
242.5%
ALNY
US$220.33
Alnylam Pharmaceuticals
7D
-23.6%
1Y
-47.4%
SMMT
US$13.05
Summit Therapeutics
7D
3.9%
1Y
-55.2%
Seeking Alpha • Jul 31

Summit Therapeutics: Upgrading To Hold As Critical Approval Decision Approaches

Summary Summit Therapeutics Inc. is upgraded from Sell to Hold as the FDA reviews its BLA for ivonescimab, with a decision expected by November 14, 2026. SMMT's pivotal HARMONI study showed statistically significant PFS but only a favorable trend in OS; updated data with a hazard ratio of 0.76 has been submitted. Competition is intensifying, with multiple large pharmas developing similar VEGF/PD-1 bispecifics; no acquisition or major partnership offers have materialized for SMMT. I remain cautious, awaiting further data readouts and clarity on SMMT’s ability to compete in the $90bn PD-1 therapy market if approval is secured. Read the full article on Seeking Alpha
INCY
US$118.43
Incyte
7D
-8.9%
1Y
52.4%
Analysis Article • Jul 31

Earnings Beat: Incyte Corporation Just Beat Analyst Forecasts, And Analysts Have Been Updating Their Models

A week ago, Incyte Corporation ( NASDAQ:INCY ) came out with a strong set of quarterly numbers that could potentially...
NTRA
US$270.36
Natera
7D
7.2%
1Y
92.9%
QURE
US$44.06
uniQure
7D
20.2%
1Y
214.7%
Narrative Update • Jul 30

QURE: Overvaluation Risks Persist As Single Huntington Filing Timeline Dominates

uniQure's updated analyst price target reflects a modest uplift in fair value to $36.30, supported by analysts' refreshed models around AMT-130's FDA-supported accelerated approval path and revised long term revenue and profitability assumptions. Analyst Commentary Recent Street research on uniQure shows a wide range of views, with many analysts updating their models around the AMT-130 program and the accelerated approval path.
VRTX
US$470.72
Vertex Pharmaceuticals
7D
-4.0%
1Y
25.5%
ONC
US$313.77
BeOne Medicines
7D
-5.1%
1Y
2.1%
Seeking Alpha • Jul 30

BeOne Medicines: Owning The Full B-Cell Treatment Sequence

Summary BeOne Medicines is transitioning from a BRUKINSA-driven story to an integrated hematology and oncology platform with multiple growth drivers. Q1 2026 results show 35.5% revenue growth, expanding margins, and rising profitability, supporting a premium valuation justified by strong operational leverage. BRUKINSA, BEQALZI, and tacabrutideg form a defensible three-asset hematology moat, while a solid-tumor pipeline and manufacturing expansion drive future diversification. Despite high concentration risk and a demanding valuation, ONC’s evolving product ecosystem and cash flow generation underpin a bullish outlook. Read the full article on Seeking Alpha
GILD
US$131.15
Gilead Sciences
7D
-2.4%
1Y
16.6%
Narrative Update • Jul 28

GILD: Future Returns Will Depend On HIV Franchise And Oncology Execution

Analysts have nudged their price targets for Gilead Sciences lower by a few dollars, generally citing updated models that factor in company commentary on Q2 R&D, a softer outlook for HIV PrEP expansion, and ongoing competitive pressure in oncology and cell therapy, alongside mixed views on the long acting HIV pipeline. Analyst Commentary Recent research on Gilead Sciences points to a more cautious tone around the stock, even as views remain mixed.